UK: Patentable Parthenotes? Advocate General Says Yes

Last Updated: 28 October 2014
Article by Henrietta Rooney and Glyn Truscott

In the latest development to the patentability of human stem cells, the Advocate General (AG) has recommended that stem cells derived from parthenogenically activated oocytes should not be excluded from patentability any longer. The AG drew the distinction between totipotent and pluripotent cells, noting that cells that do not have the capacity to develop into a human being should not be excluded from patentability.

Good news could be on the horizon for stem cell patenting in Europe, following the AG opinion in the most recent stem cell case to be considered by the CJEU (C-364/13). The AG has recommended that unfertilized human ova that have been stimulated to develop by parthenogenesis are excluded from the definition of "human embryo" and are therefore back in the realm of patentable subject matter. If the CJEU follows this recommendation, it would refine the position established in the Brüstle decision in 2011 (C 34/10).


International Stem Cell Corporation (ISC) applied to the UK Intellectual Property Office (UK IPO) for two patents (GB0621068.6 and GB0621069.4) for inventions that related to stem cells derived from parthenogenetically activated oocytes. These applications claimed methods of producing pluripotent human stem cell lines from parthenogenetically-activated oocytes, stem cell lines produced according to the claimed methods and methods of producing synthetic cornea or corneal tissue involving the isolation of pluripotent stem cells from parthenogenetically-activated oocytes.

The UK IPO refused these applications on the grounds that the inventions covered uses of human embryos as defined by the Court of Justice in Brüstle. At first reading, the IPO's decision to refuse ISC's applications seems clear-cut. The Brüstle decision on the meaning of a "human embryo" in the sense of Article 6(2)(c) of EU Directive 98/44/EC on the legal protection of biotechnological inventions (the Biotech Directive) appears to exclude parthenogenetically-activated oocytes, otherwise known as parthenotes, from patentability. However, an inconsistency in the technical reasoning regarding the nature of parthenotes makes this exclusion less clear. ISC appealed the IPO's refusals to the High Court, which in turn asked the CJEU for clarification as to whether parthenotes should be considered to be human embryos.

Technical background

Human development typically starts with the fertilisation of a human ovum. Over the next five days, the cells in the fertilized ovum, or zygote, divide rapidly and then begin to differentiate into different types of cells. By day five, a structure called a blastocyst has formed. The blastocyst contains different types of cells, some of which will go on to form the body of the embryo and some of which will go on to form other structures such as the placenta, referred to as extra-embryonic tissues. Both are essential for development of the blastocyst into a human being.

Embryonic stem cells are commonly derived from human embryos in these early stages of development. These stem cells can be divided into different categories, depending on their potential to develop and change into different types of cells. "Totipotent" cells are capable of developing into all human cell types, while "pluripotent" cells can only develop into the cell types that make up the body, and not into extra-embryonic tissues. Therefore, pluripotent cells cannot develop into a human being.

At the time of the present referral it was agreed by all parties that, according to current scientific knowledge, a human parthenote cannot develop past the blastocyst stage. A parthenote has not been fertilized and so only contains maternal DNA. Consequently, a parthenote cannot develop all extra-embryonic tissues, and so cannot develop into a human being. It is generally accepted that mammalian parthenotes are not able to develop to full term without further intervention.

The technical evidence presented in the Brüstle case was different. In that decision, the CJEU did not make any technical distinction between (i) fertilised ova, (ii) non-fertilised ova subjected to somatic-cell nuclear transfer and (iii) parthenotes. In fact, the court commented that parthenotes "are, as is apparent from the written observations presented to the Court, capable of commencing the process of development of a human being just as an embryo created by fertilisation of an ovum can do so". It was against this background that the CJEU decided that parthenotes were within the definition of "human embryos".

What did the CJEU mean by "capable of commencing" in Brüstle?

In Brüstle, the CJEU held that the definition of a human embryo must be understood in a wide sense, so any inventions that do not respect human dignity are excluded from patentability. Consequently, the CJEU defined a human embryo as "any human ovum after fertilisation, any non-fertilised human ovum into which the cell nucleus from a mature human cell has been transplanted, and any non-fertilised human ovum whose division and further development have been stimulated by parthenogenesis". The decision was informed by technical submissions from both sides about the developmental potential of cells derived from human embryos at various stages in their development, and was intended to exclude from patentability any cells that are "capable of commencing the process of development of a human being".

The crux of the new referral was therefore the meaning of the term "capable of commencing the process of development of a human being". Does this mean that the first developmental steps mimic the development of a fertilized ovum, i.e. cell division and differentiation similar to that of a fertilised ovum, or is the outcome more significant, i.e. must the cells possess the capacity to develop into a human being?

The UK High Court favoured the latter interpretation, and so referred the following question to the CJEU:

"Are unfertilised human ova whose division and further development have been stimulated by parthenogenesis, and which, in contrast to fertilised ova, contain only pluripotent cells and are incapable of developing into human beings, included in the term "human embryos" in Article 6(2)(c) of Directive 98/44 on the Legal Protection of Biotechnological Inventions?".

Crucially, this question is limited to those parthenotes that are incapable of developing into human beings.

Future-proofing the definition

In revisiting the issues of the patentability of stem cells, the AG has answered a slightly different question than that referred in Brüstle. The need for a further referral to clarify the patentability of human embryonic stem cells highlights the difficulty in making decisions in technical fields that are changing at such a rapid pace. On reflection, three years down the line, it might be said that the CJEU erred in excluding parthenotes from patentability and including them in the same category as fertilised ova and non-fertilised ova subjected to somatic-cell nuclear transfer. Both of these have a full complement of maternal and paternal DNA, and are capable of developing into a human being. A parthenote, we now know, is not.

How then, to future-proof the definition? Are we likely to find ourselves in another three years' time in a position where it is technically possible to coax a parthenote to develop into a human being?

The AG clearly had this in mind, and therefore answered the referred question with a caveat: a parthenote is not a human embryo but only as long as it is not capable of developing into a human being and has not been genetically manipulated to acquire such a capacity.

The AG's opinion brings us firmly back to the fundamental reasons for the Biotech Directive: the need to respect human dignity and exclude human beings, at any stage of development, from patentability. However, where there is no capacity to develop into a human being, there is no justification for a centralised exclusion from patentability across the whole of Europe. It remains to be seen whether the court agrees with the AG's opinion, and whether the AG's suggested caveat on genetic manipulation goes far enough.

Need advice?

For more information, please contact

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at

This Briefing Note was first published in the IAM IP Newsletter.

Carpmaels & Ransford LLP is a leading firm of European patent attorneys based in London. For more information about our firm and our practice, please visit our website at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.